A Phase 3 interventional study of Alogliptin and Placebo to alogliptin in Diabetes Mellitus, Type 2, sponsored by Takeda. Completed at 21 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-03-22.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing alogliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus, Type 2.
Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is the only one that started in 2010, is one of 16 in phase 3, and was the 21st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 23 · Phase 4 9
First in 2005; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 506 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 329 across the 39 interventional studies. Of the 35 that completed or were terminated, 30 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 9 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
105 studies in Diabetes Mellitus, Type 2 by Takeda: none open now, none under way, none of them phase 3. Of 103 finished, 69 (67%) have results posted.
Among the 105 studies in Diabetes Mellitus, Type 2 by Takeda, this one is the 19th largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2010, is one of 45 in phase 3, and was the 57th registered.
Takeda’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 105 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the efficacy of alogliptin compared to placebo when given alone or as add-on therapy to metformin or add-on to pioglitazone (with or without metformin).
Diabetes is a chronic illness associated with microvascular complications such as nephropathy (kidney disease), retinopathy (eye damage) and neuropathy (nervous system damage). Diabetes is also associated with macrovascular complications including cardiovascular disease (heart disease), stroke and peripheral vascular disease (narrowing or blockage of blood vessels). These complications are associated with reduced quality of life and increased morbidity and mortality.
Takeda is developing SYR-322 (alogliptin) for improvement of glycemic control in patients with Type 2 diabetes mellitus.
Evaluations of alogliptin and its clinical efficacy have been conducted in multiple countries including the United States and Japan. This study will be conducted as a multi-center clinical trial in order to validate the efficacy and safety of alogliptin on type 2 diabetes population within Asia.
Participants who qualified for the study were stratified into 1 of the 3 therapy groups based upon their background antidiabetic therapy before being randomized 1:1 to receive either alogliptin 25 mg once daily or matching placebo once daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
Drug: Placebo to alogliptin
Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
Drug: Alogliptin
Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
Drug: Placebo to alogliptin · Drug: Metformin
Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
Drug: Alogliptin · Drug: Metformin
Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
Drug: Placebo to alogliptin · Drug: Pioglitazone
Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.
Drug: Alogliptin · Drug: Pioglitazone
Alogliptin tablets
Also known as: SYR-322
Alogliptin placebo-matching tablets.
Stable metformin dose
Also known as: Fortamet, Glucophage, Glumetza
Stable pioglitazone dose
Also known as: Actos
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 16. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.
Time frame: Baseline and Week 16.
Change From Baseline in HbA1c Over Time
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Weeks 4, 8 and 12. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.
Time frame: Baseline and Weeks 4, 8 and 12.
Change From Baseline in Fasting Plasma Glucose Over Time
The change from Baseline in fasting plasma glucose (FPG) at Weeks 4, 8, 12 and 16. Least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline FPG as a covariate for the monotherapy, baseline FPG with baseline metformin dose as covariates for the metformin therapy, baseline FPG with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.
Time frame: Baseline and Weeks 4, 8, 12 and 16.
Percentage of Participants With Marked Hyperglycemia
Marked Hyperglycemia was defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L).
Time frame: Randomization to Week 16.
Change From Baseline in Body Weight
The change between body weight measured at Baseline and body weight measured at Weeks 8 and 16. The least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline body weight as a covariate for the monotherapy, baseline body weight with baseline metformin dose as covariates for the add-on to metformin therapy, baseline body weight with baseline metformin therapy status and baseline pioglitazone dose as covariates for the add-on to pioglitazone therapy.
Time frame: Baseline and Weeks 8 and 16.
Percentage of Participants With HbA1c ≤6.5% at Week 16
Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 6.5% at Week 16.
Time frame: Week 16
Percentage of Participants With HbA1c ≤7.0% at Week 16
Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.0% at Week 16.
Time frame: Week 16
Percentage of Participants With HbA1c ≤7.5% at Week 16
Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.5% at Week 16.
Time frame: Week 16
Percentage of Participants With a Decrease in HbA1c ≥ 0.5%
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5% at Week 16.
Time frame: Baseline and Week 16
Percentage of Participants With a Decrease in HbA1c ≥1.0%
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.0% at Week 16.
Time frame: Baseline and Week 16
Percentage of Participants With a Decrease in HbA1c ≥1.5%
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5% at Week 16.
Time frame: Baseline and Week 16.
Percentage of Participants With a Decrease in HbA1c ≥2.0%
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0% at Week 16.
Time frame: Baseline and Week 16.
Participants took part in the study at 30 investigative sites in China, Taiwan province and Hong Kong from 23 December 2010 to 19 December 2011.
| Milestone | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Started | 93 | 92 | 98 | 99 | 63 | 61 |
| Treated | 92 | 92 | 98 | 99 | 63 | 61 |
| Completed | 84 | 83 | 89 | 93 | 58 | 57 |
| Not completed | 9 | 9 | 9 | 6 | 5 | 4 |
| Withdrew: Adverse event | 2 | 1 | 0 | 2 | 1 | 0 |
| Withdrew: Major protocol deviation | 2 | 1 | 3 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 2 | 4 | 3 | 1 | 1 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 | 1 | 1 | 1 |
| Withdrew: Other | 1 | 0 | 1 | 0 | 0 | 0 |
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 16. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.
| percentage glycosylated hemoglobin | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) | -0.42 ± 0.074 | -0.99 ± 0.074 | -0.22 ± 0.065 | -0.91 ± 0.065 | -0.25 ± 0.097 | -0.76 ± 0.101 |
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Weeks 4, 8 and 12. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.
| percentage glycosylated hemoglobin | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Week 4 (n=90, 88, 97, 98, 63, 60) | -0.24 ± 0.059 | -0.56 ± 0.059 | -0.15 ± 0.036 | -0.43 ± 0.036 | -0.09 ± 0.064 | -0.44 ± 0.066 |
| Week 8 (n=90, 90, 97, 98, 63, 60) | -0.39 ± 0.068 | -0.86 ± 0.068 | -0.15 ± 0.057 | -0.66 ± 0.057 | -0.31 ± 0.094 | -0.70 ± 0.098 |
| Week 12 (n=90, 90, 97, 98, 63, 60) | -0.41 ± 0.078 | -0.99 ± 0.078 | -0.24 ± 0.069 | -0.86 ± 0.068 | -0.25 ± 0.102 | -0.77 ± 0.106 |
The change from Baseline in fasting plasma glucose (FPG) at Weeks 4, 8, 12 and 16. Least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline FPG as a covariate for the monotherapy, baseline FPG with baseline metformin dose as covariates for the metformin therapy, baseline FPG with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.
| mmol/L | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Week 4 (n=89, 87, 97, 97, 63, 60) | -0.331 ± 0.1221 | -0.719 ± 0.1235 | -0.251 ± 0.1454 | -0.985 ± 0.1454 | 0.284 ± 0.2505 | -0.985 ± 0.2603 |
| Week 8 (n=89, 89, 97, 97, 63, 60) | -0.330 ± 0.1224 | -1.015 ± 0.1224 | -0.235 ± 0.1397 | -1.265 ± 0.1397 | -0.038 ± 0.2503 | -0.924 ± 0.2600 |
| Week 12 (n=89, 89, 97, 97, 63, 60) | -0.411 ± 0.1515 | -1.123 ± 0.1515 | -0.335 ± 0.1600 | -1.270 ± 0.1600 | -0.187 ± 0.2484 | -1.177 ± 0.2581 |
| Week 16 (n=89, 89, 97, 97, 63, 60) | -0.317 ± 0.1556 | -1.243 ± 0.1556 | -0.512 ± 0.1565 | -1.240 ± 0.1565 | -0.114 ± 0.2579 | -1.070 ± 0.2679 |
Marked Hyperglycemia was defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L).
| percentage of participants | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Percentage of Participants With Marked Hyperglycemia | 16.9 | 4.5 | 25.8 | 13.4 | 23.8 | 8.3 |
The change between body weight measured at Baseline and body weight measured at Weeks 8 and 16. The least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline body weight as a covariate for the monotherapy, baseline body weight with baseline metformin dose as covariates for the add-on to metformin therapy, baseline body weight with baseline metformin therapy status and baseline pioglitazone dose as covariates for the add-on to pioglitazone therapy.
| kg | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Week 8 (n=87, 86, 94, 96, 63, 59) | -1.04 ± 0.210 | -0.71 ± 0.211 | -0.82 ± 0.170 | -0.43 ± 0.168 | -0.74 ± 0.286 | -0.15 ± 0.304 |
| Week 16 (n=88, 87, 94, 96, 63, 59) | -1.55 ± 0.244 | -0.89 ± 0.245 | -1.06 ± 0.219 | -0.76 ± 0.217 | -0.68 ± 0.364 | -0.10 ± 0.388 |
Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 6.5% at Week 16.
| percentage of participants | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Percentage of Participants With HbA1c ≤6.5% at Week 16 | 12.2 | 36.7 | 4.1 | 21.4 | 9.5 | 30.0 |
Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.0% at Week 16.
| percentage of participants | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Percentage of Participants With HbA1c ≤7.0% at Week 16 | 30.0 | 63.3 | 25.8 | 55.1 | 31.7 | 61.7 |
Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.5% at Week 16.
| percentage of participants | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Percentage of Participants With HbA1c ≤7.5% at Week 16 | 53.3 | 81.1 | 50.5 | 80.6 | 47.6 | 85.0 |
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5% at Week 16.
| percentage of participants | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Percentage of Participants With a Decrease in HbA1c ≥ 0.5% | 41.1 | 84.4 | 37.1 | 70.4 | 42.9 | 76.7 |
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.0% at Week 16.
| percentage of participants | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Percentage of Participants With a Decrease in HbA1c ≥1.0% | 20.0 | 50.0 | 9.3 | 45.9 | 19.0 | 46.7 |
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5% at Week 16.
| percentage of participants | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Percentage of Participants With a Decrease in HbA1c ≥1.5% | 7.8 | 23.3 | 1.0 | 22.4 | 7.9 | 8.3 |
Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0% at Week 16.
| percentage of participants | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Percentage of Participants With a Decrease in HbA1c ≥2.0% | 2.2 | 8.9 | 0.0 | 9.2 | 1.6 | 3.3 |
Collected over Treatment-emergent adverse events (TEAE) were defined as any adverse events that started on or after the date of the first dose of double-blind study drug and within 14 days after the date of the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/92 (2.2%) | 11/92 (12%) |
| Alogliptin Monotherapy | — | 2/92 (2.2%) | 12/92 (13%) |
| Metformin | — | 3/98 (3.1%) | 8/98 (8.2%) |
| Metformin + Alogliptin Add-on Therapy | — | 0/99 (0%) | 7/99 (7.1%) |
| Pioglitazone | — | 0/63 (0%) | 14/63 (22.2%) |
| Pioglitazone + Alogliptin Add-on Therapy | — | 1/61 (1.6%) | 18/61 (29.5%) |
| Event | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| Lacunar infarctionNervous system disorders | 0/92 | 0/92 | 0/98 | 0/99 | 0/63 | 1/61 |
| Pancreatitis acuteGastrointestinal disorders | 1/92 | 0/92 | 0/98 | 0/99 | 0/63 | 0/61 |
| Cholangitis acuteHepatobiliary disorders | 0/92 | 1/92 | 0/98 | 0/99 | 0/63 | 0/61 |
| CellulitisInfections and infestations | 1/92 | 0/92 | 0/98 | 0/99 | 0/63 | 0/61 |
| Intraductal papilloma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/92 | 1/92 | 0/98 | 0/99 | 0/63 | 0/61 |
| Atrial fibrillationCardiac disorders | 0/92 | 0/92 | 1/98 | 0/99 | 0/63 | 0/61 |
| Coronary artery diseaseCardiac disorders | 0/92 | 0/92 | 1/98 | 0/99 | 0/63 | 0/61 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/92 | 0/92 | 1/98 | 0/99 | 0/63 | 0/61 |
| HypertensionVascular disorders | 0/92 | 0/92 | 1/98 | 0/99 | 0/63 | 0/61 |
| Event | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy |
|---|---|---|---|---|---|---|
| HyperlipidaemiaMetabolism and nutrition disorders | 1/92 | 6/92 | 0/98 | 0/99 | 4/63 | 13/61 |
| Upper respiratory tract infectionInfections and infestations | 3/92 | 5/92 | 5/98 | 3/99 | 6/63 | 2/61 |
| Urinary tract infectionInfections and infestations | 6/92 | 2/92 | 2/98 | 2/99 | 1/63 | 4/61 |
| Blood triglycerides increasedInvestigations | 1/92 | 2/92 | 2/98 | 2/99 | 4/63 | 0/61 |
| Age Continuous(years) | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy | Total |
|---|---|---|---|---|---|---|---|
| Mean | 53.1 ± 8.88 | 51.6 ± 10.41 | 53.2 ± 9.46 | 53.0 ± 9.88 | 51.8 ± 10.37 | 52.6 ± 9.44 | 52.6 ± 9.71 |
| Age, Customized(participants) | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy | Total |
|---|---|---|---|---|---|---|---|
| <65 Years | 81 | 80 | 86 | 85 | 56 | 52 | 440 |
| ≥65 years | 12 | 12 | 12 | 14 | 7 | 9 | 66 |
| Sex: Female, Male(Participants) | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy | Total |
|---|---|---|---|---|---|---|---|
| Female | 39 | 37 | 50 | 48 | 24 | 33 | 231 |
| Male | 54 | 55 | 48 | 51 | 39 | 28 | 275 |
| Race/Ethnicity, Customized(participants) | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy | Total |
|---|---|---|---|---|---|---|---|
| Number | 93 | 92 | 98 | 99 | 63 | 61 | 506 |
| Region of Enrollment(participants) | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy | Total |
|---|---|---|---|---|---|---|---|
| Taiwan | 1 | 0 | 2 | 3 | 0 | 0 | 6 |
| Hong Kong | 1 | 2 | 2 | 4 | 0 | 0 | 9 |
| China | 91 | 90 | 94 | 92 | 63 | 61 | 491 |
| Height(cm) | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy | Total |
|---|---|---|---|---|---|---|---|
| Mean | 165.4 ± 7.19 | 165.9 ± 8.61 | 164.8 ± 8.47 | 165.7 ± 9.06 | 166.2 ± 8.87 | 163.0 ± 7.06 | 165.2 ± 8.31 |
| Weight(kg) | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy | Total |
|---|---|---|---|---|---|---|---|
| Mean | 70.86 ± 10.464 | 71.16 ± 11.065 | 69.67 ± 11.792 | 71.20 ± 13.473 | 72.44 ± 11.989 | 67.59 ± 11.989 | 70.55 ± 11.856 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Alogliptin Monotherapy | Metformin | Metformin + Alogliptin Add-on Therapy | Pioglitazone | Pioglitazone + Alogliptin Add-on Therapy | Total |
|---|---|---|---|---|---|---|---|
| Mean | 25.86 ± 3.002 | 25.79 ± 3.086 | 25.54 ± 2.876 | 25.75 ± 3.122 | 26.13 ± 3.031 | 25.32 ± 3.223 | 25.73 ± 3.042 |
4 further baseline measures are reported on the registry.
The record gives a start of Dec 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alogliptin · Metformin · Pioglitazone